AZD8421 + camizestrant

AZD8421 + camizestrant is an investigational oral combination therapy under clinical development for the treatment of advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and other selected solid tumors. - **AZD8421** is a potent and selective small molecule inhibitor of cyclin-dependent kinase 2 (CDK2), a key regulator of cell cycle progression implicated in resistance to endocrine therapies in ER+ cancers. - **Camizestrant** (also known as AZD9833) is a next-generation, oral selective estrogen receptor degrader (SERD) and complete estrogen receptor antagonist that targets the estrogen receptor pathway, which drives tumor growth in HR-positive breast cancer. The combination aims to overcome resistance mechanisms by simultaneously inhibiting CDK2-driven cell proliferation and degrading the estrogen receptor, thereby providing a dual blockade of critical pathways involved in tumor progression. The regimen is being evaluated alone or with additional CDK4/6 inhibitors such as abemaciclib, ribociclib, or palbociclib[1][5][7][8].

Other names

camizestrant